Puretech Presents New Data From Phase 2b Open-Label Extension Study Of Deupirfenidone
View all comments(0)
Sept 29 (Reuters) - PureTech Health PLC PRTC.L:
PURETECH PRESENTS NEW DATA FROM PHASE 2B OPEN-LABEL EXTENSION STUDY OF DEUPIRFENIDONE (LYT-100), FURTHER SUPPORTING STRONG AND DURABLE EFFICACY AND POTENTIAL TO SERVE AS NEW STANDARD OF CARE IN IPF
PURETECH HEALTH PLC - PATIENTS SWITCHING TO DEUPIRFENIDONE ACHIEVED LUNG FUNCTION STABILIZATION WITH FAVORABLE TOLERABILITY
PURETECH HEALTH PLC - PHASE 3 TRIAL DESIGN UPDATE EXPECTED Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.